2006;114:e385 484. S10.7-15. Behr ER, Ritchie MD, Tanaka T, et al. Genome wide analysis of drug- induced torsades de pointes: lack of common variants with large effect sizes. PloS One. 2013;8:e78511. S10.7-16. Kaab S, Crawford DC, Sinner MF, et al. A large candidate gene sur- vey identifies the KCNE1 D85N polymorphism as a possible modu- lator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012;5:91 9. S10.7-17. Strauss DG, Vicente J, Johannesen L, et al. A common genetic variant risk score is associated with drug-induced QT prolon- gation and torsade de pointes risk: a pilot study. Circulation. 2017;135:1300 10. S10.7-18. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT dis- ease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943 8. S10.7-19. Weeke P, Mosley JD, Hanna D, et al. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol. 2014;63:1430 7. S10.7-20. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781 8. S10.7-21. Chamberlain DA, Jewitt DE, Julian DG, et al. Oral mexiletine in high- risk patients after myocardial infarction. Lancet. 1980;2:1324 7. S10.7-22. UK Rythmodan Multicentre Study Group Oral disopyramide after admission to hospital with suspected acute myocardial infarc- tion. U. K. Rythmodan Multicentre Study Group. Postgrad Med J. 1984;60:98 107. S10.7-23. Crijns HJ, Van Gelder IC, Lie KI, Supraventricular tachycardia mim- icking ventricular tachycardia during flecainide treatment. Am J Cardiol. 1988;62:1303 6. S10.7-24. Alings M, Wilde A, Brugada syndrome: clinical data and suggested pathophysiological mechanism. Circulation. 1999;99:666 73. S10.7-25. Konigstein M, Rosso R, Topaz G, et al. Drug-induced Brugada syndrome: clinical characteristics and risk factors. Heart Rhythm. 2016;13:1083 7. S10.7-26. 